ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. december 17, 2018
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome Press release Key updates mei 01, 2017
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A Press release Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. februari 12, 2018
ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients Press release Topline data to be presented today at NACFC oktober 27, 2016
ProQR Therapeutics Announces Results for the First Quarter of 2015 Press release LEIDEN, the Netherlands, May 21, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. mei 21, 2015
ProQR Announces Results for the First Quarter of 2016 Press release LEIDEN, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. mei 18, 2016
ProQR Therapeutics Announces Results for the Third Quarter of 2014 Press release LEIDEN, the Netherlands, Nov. 24, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. november 24, 2014
ProQR Announces Proposed Public Offering of Ordinary Shares Press release LEIDEN, the Netherlands, Nov. november 13, 2017
ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference Press release LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. juni 01, 2016